InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

EXELIXIS, INC.

EXEL Clue Score84
United States Fiscal year ends January CIK 0000939767 Results filed 29 Oct 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

16
Insider
Date
Role
Action
Shares
Price
Amount
Dana Aftab
26 May 2026
EVP, Research and Development
Sell
43,451
$50.35
$2.19M
Patrick J. Haley
20 May 2026
EVP, Commercial
Sell
32,110
$49.81
$1.60M
Christopher J. Senner
18 May 2026
EVP and CFO
Sell
34,901
$50.00
$1.75M
George Poste
7 May 2026
Director
Sell
60,000
$45.71
$2.74M
Dana Aftab
24 Feb 2026
EVP, Research and Development
Sell
47,918
$44.50
$2.13M
Dana Aftab
19 Feb 2026
EVP, Research and Development
Sell
29,873
$44.35
$1.32M
Patrick J. Haley
17 Feb 2026
EVP, Commercial
Sell
64,778
$43.50
$2.82M
Patrick J. Haley
17 Feb 2026
EVP, Commercial
Sell
3,036
$43.84
$133.10K
Christopher J. Senner
17 Feb 2026
EVP and CFO
Sell
30,617
$43.67
$1.34M
Christopher J. Senner
13 Feb 2026
EVP and CFO
Sell
34,278
$43.00
$1.47M
Patrick J. Haley
21 Nov 2025
EVP, Commercial
Sell
28,043
$42.58
$1.19M
Patrick J. Haley
20 Nov 2025
EVP, Commercial
Sell indirect
10,648
$41.77
$444.77K
Patrick J. Haley
20 Nov 2025
EVP, Commercial
Sell indirect
23,539
$41.93
$986.99K
Patrick J. Haley
20 Nov 2025
EVP, Commercial
Sell
10,000
$42.11
$421.10K
Stelios Papadopoulos
12 Nov 2025
Director
Sell
100,000
$43.55
$4.36M
Dana Aftab
11 Nov 2025
EVP, Research and Development
Sell
48,383
$42.50
$2.06M
Show all 34 transactions →

What was left out

Form 4 filings counted 53
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 6
Sales straight out of an exercise 10
Sales at will 16
Transactions with no price 0
Shares from compensation/vesting 4,810,436
History held since 6 Oct 2006